Illumina (ILMN) just expanded its collaboration with Labcorp, centering investor attention on how next generation sequencing in precision oncology might influence the company’s role in cancer testing and broader genomic diagnostics.

At a share price of US$120.81, Illumina has a 1 day share price return of 2.67%, while its 30 day and year to date share price returns show declines of around 10%. This contrasts with a 52.27% 1 year total shareholder return and suggests that earlier momentum has cooled recently.

If this collaboration has you thinking about where genomics and AI intersect in healthcare, it could be worth scanning a wider field of opportunities through our 34 healthcare AI stocks

So with Illumina trading at US$120.81, sitting at a 19% intrinsic discount and about 13% below analyst targets after years of mixed shareholder returns, is the recent pullback creating an entry point, or is the market already pricing in future growth?

Most Popular Narrative: 11.2% Undervalued

Illumina's most followed narrative places fair value at about US$136 per share, compared with the current US$120.81 price, and builds that gap using detailed cash flow, growth, and margin assumptions under a discount rate of 8.07%.

Strong and resilient growth in clinical applications especially oncology, genetic disease testing, and reproductive health continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility. Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables. This positions the business for sustained volume and revenue growth.

Curious what sits behind that valuation gap? This narrative leans heavily on measured revenue growth, steadier profit margins, and a future earnings multiple that still sits below many tools peers. The tension is how those ingredients combine to justify an intrinsic value above both the market price and the analyst target.

Result: Fair Value of $136.05 (UNDERVALUED)

However, there is still clear risk that tighter research budgets and ongoing regulatory pressure in China could undercut the revenue and margin assumptions behind that 11.2% discount.

Next Steps

Mixed signals on value and risks so far? Take a moment to review the data for yourself, and weigh both sides with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Illumina has caught your attention, do not stop here. Broader context from other opportunities can sharpen your judgement and help you act with more confidence.

• Spot potential bargains early by checking companies that look mispriced on fundamentals through the 62 high quality undervalued stocks.
• Prioritise resilience by reviewing businesses with stronger financial footing using the solid balance sheet and fundamentals stocks screener (39 results).
• Hunt for under followed opportunities that the market may be overlooking with the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.